Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 62

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 62
---
 and the new exercise price of $0.80. The
deemed dividend increased net loss attributable to common shareholders by $83,083 in the condensed consolidated statement of operations
for the nine months ended September 30, 2025. The fair value of the Series C Common Warrants immediately prior to and immediately after
the exercise price adjustment, were estimated using the Black-Scholes option-pricing model with the following assumptions:

|                                 |     |      February 5, 
             2025 |
|:--------------------------------|:----|-----------------:|
| Exercise price                  |     | $0.80 to $196.00 |
| Term (years)                    |     |              3.0 |
| Expected stock price volatility |     |          109.17% |
| Risk-free rate of interest      |     |            4.19% |

The Company’s Series
C Common Warrants are exercisable into Common Stock and are recorded as equity.

<div align='center'>24</div>

December 2024 and January 2025 Common Warrants (Successor)

On December 23, 2024, the
Company issued warrants to purchase an aggregate of 4,203 shares of Common Stock to certain investors affiliated with each other to induce
investors to exercise their Series A Preferred Warrants for cash (the “December 2024 Common Warrants”). The December 2024
Common Warrants are exercisable for cash at an initial exercise price equal to $112.20 (as adjusted for stock splits, stock dividends,
stock combinations, recapitalizations and similar events). The December 2024 Common Warrants are exercisable beginning six months after
the issuance date (the “Initial Exercisability Date”) and expire on the third anniversary of the Initial Exercisability Date.
The December 2024 Common Warrants require “buy-in” payments to be made by us for failure to deliver any shares of Common Stock
issuable upon exercise. If at the time of exercise of the December 2024 Common Warrants, there is no effective registration statement
registering the shares of the Common Stock underlying the December 2024 Common Warrants, such warrants may be exercised on a cashless
basis pursuant to their terms.

On January 6, 2025, the Company
issued warrants to purchase an aggregate of 8,193 shares of Common Stock to certain investors affiliated with each other to induce investors
to exercise their Series A Preferred Warrants for